



The ROYAL COLLEGE of  
OPHTHALMOLOGISTS

---

Guidance document

# Prioritisation of ophthalmic outpatient appointments

May 2020

18 Stephenson Way, London, NW1 2HD, T. 0203770532  
contact@rcophth.ac.uk @rcophth.ac.uk

The Royal College of Ophthalmologists 2020 All rights reserved.

For permission to reproduce any of the content contained herein please contact contact@rcophth.ac.uk

---

## Contents

---

Section	page
1 Introduction	3
2 Levels of risk associated with delaying appointments and lost to follow up	3
3 Level 1: Emergency appointments (same day, may be in A&E)	5
4 Level 2: Urgent appointments needed within 7 days	7
5 Level 3: Appointments within 14 days	9
6 Level 4: Appointments within 30 days	11
7 Level 5: Appointment above 30 days, safe date needs identification per patient	13
8 References	15

## 1 Introduction

---

The SARS-CoV-2 pandemic has caused dramatic changes to the provision of medical services within the UK and has caused a reduction in ophthalmic services being provided to reduce the spread of the disease. This guidance has been developed to aid ophthalmic services in the prioritisation of their outpatient capacity of their departments. The majority of outpatient appointment types are covered within this guidance however it is not an exhaustive list and services may wish to adapt this list to create a prioritisation system which best suits the population which they provide an ophthalmic service.

Outpatient appointments have been broken down into the following priority levels:

- Level 1: Emergency appointment same day
- Level 2: Appointment within 7 days
- Level 3: Appointment within 14 days
- Level 4: Appointment within 30 days
- Level 5: Appointment above 30 days, safe date needs identification per patient

These time intervals have been based on usual accepted practice and developments in that during the lockdown period, and where delaying these appointment times may result in greater risk of an adverse outcome for the patient due to progression or worsening of the condition being treated/monitored.

## 2 Levels of risk associated with delaying appointments and lost to follow up

---

Ophthalmic services have been put under severe pressure due to the SARS-CoV-2 pandemic. It is crucial that patients are not lost during this period of reduced service and during the subsequent recovery to business as usual. With the extra pressure the pandemic has put on services, it is clear that some patients with lower risk conditions will need to have their appointments delayed to allow for the patient's at higher risk of visual loss to be seen. Clear records must be kept detailing any decision to delay a patient's outpatient appointment and a coordinated review of delayed patients must be undertaken at regular intervals to ensure patients are not coming to harm due to being deferred. Any decision to defer a patient must evaluate the risk that the patient will come to harm due to the delay in any treatment the patient would subsequently receive.

All outpatient appointments in the priority levels below have been colour coded according to the risk of harm to the patient of any decision to delay an outpatient appointment:

Level of Risk	Colour Code
High Risk	Red
Medium Risk	Yellow
Low Risk	Green

Although these appointments have been coded according to risk, individual patient circumstance (for example someone with only one good seeing eye) may mean that a patient does not fall under the same risk category as highlighted below and ophthalmologists must have the discretion to assign risk based on clinical judgement.

In the tables below, please note some appointments straddle more than one subspecialty and to be concise have **not** been noted in both.

### 3 Level 1: Emergency appointments (same day, may be in A&E)

<b>Vitreoretinal</b>	Vitreous haemorrhage if risk retinal tear or detachment	Trauma	Retinal detachment					
<b>Neuro-ophthalmology</b>	Giant cell arteritis with visual disturbance or diplopia	Acute third nerve palsy Acute sixth nerve palsy	Acute painful Horner's	Papilloedema	Neurological acute loss of vision under 50 years old	Amaurosis fugax	Possible myasthenia gravis with bulbar or respiratory symptoms	Acute homonymous or bitemporal field loss
<b>Medical Retina and Uveitis</b>	Severe infectious retinitis and chorioretinitis with rapid loss of vision	Endophthalmitis	Severe necrotising or infectious scleritis	Severe non-infectious uveitis with rapid vision loss	Central retinal artery occlusion if within 8 hours of onset (otherwise less urgent)			
<b>Glaucoma</b>	Acute angle closure glaucoma	Other acute very high IOP >40mmHg						

<b>Adnexal</b>	Trauma to lids or tear ducts	Orbital inflammation or tumour or haemorrhage with imminent threat to cornea or optic nerve	Orbital cellulitis					
<b>Trauma</b>	Penetrating or intraocular foreign body	Severe chemical burn to the eye	Penetrating injury	Severe blunt trauma				
<b>External and corneal</b>	Acute very severe corneal pathology	Severe acute microbial or inflammatory keratitis	Actual or imminent corneal perforation					
<b>Paediatrics</b>	As per adults as described in the other rows							

## 4 Level 2: Urgent appointments needed within 7 days

<b>Vitreoretinal</b>	Retinal tear					
<b>Neuro-ophthalmology</b>	Optic neuritis	Corneal exposure from acute facial nerve palsy	Patients losing vision due to neuro-ophthalmic condition	Acute loss of vision (neurological cause) >50 yo	Sudden onset strabismus, likely neurological cause	
<b>Medical Retina and Uveitis</b>	Severe non-Infectious uveitis or scleritis with reduced vision	Painful recurrence of anterior uveitis	Infectious retinitis or chorioretinitis with reduced vision	Neovascular age-related macular degeneration in 2-stop treatment model		
<b>Glaucoma</b>	High risk avoidable vision loss within 2 months –	Post-op patients with surgery within 6/52 of trabeculectomy; 3/12 of tube surgery				
<b>Adnexal</b>	Severe inflammatory orbital and lid disease	Visual loss secondary to adnexal conditions e.g. orbital compression	Severe thyroid eye disease			

<b>External</b>	Severe keratitis	Corneal graft rejection	Corneal ulcer or microbial keratitis	Acute severe ocular surface inflammatory disease eg MMP, SJS		
<b>Paediatrics</b>	Cataracts causing amblyopia or under 8 months old	Retinopathy of prematurity screening	Orbital non infective inflammation and Preseptal cellulitis	Suspect glaucoma	Swollen optic nerves with symptoms	Symptomatic uveitis

## 5 Level 3: Appointments within 14 days

<b>Vitreoretinal</b>	Complex surgery post-ops			
<b>Neuro-ophthalmology</b>	New onset acquired nystagmus	<u>Asymptomatic</u> possible mild optic disc swelling (NOT likely papilloedema)	Potential myasthenia gravis <u>without</u> systemic symptoms	
<b>Medical Retina and Uveitis</b>	Other choroidal neovascularization	Neovascular age-related macular degeneration in 1-stop treatment model	Active uveitis or scleritis with significant pain and/or visual symptoms	
<b>Paediatrics</b>	Leukocoria or abnormal red reflex	Acquired nystagmus	Sudden onset strabismus, likely neurological cause	
<b>Adnexal</b>	Lid oncology	Tumours of lacrimal system and orbit	Adnexal care for sight threatening ocular surface disease	

<b>Trauma</b>	Orbital floor fractures			
<b>Cataract</b>	Complicated post-op / follow-up cataract surgery (uveitis/CMO/others)			
<b>Other</b>	Ocular oncology			

## 6 Level 4: Appointments within 30 days

---

<b>Vitreoretinal</b>				
<b>Neuro-ophthalmology</b>	Acute 4th nerve palsy			
<b>Medical Retina and Uveitis</b>	Central retinal vein occlusion	Proliferative diabetic retinopathy	Review post intraocular steroid implant for uveitis	
<b>Glaucoma</b>	High risk avoidable vision loss within 4-6 months			
<b>Oncology</b>				

<b>Adnexal</b>	Visually disabling blepharospasm			
<b>Cataract</b>	Cataract with best seeing eye below 6/60 , risk of fall/injury/inability to function	Cataract/PCO with best seeing eye <6/18 and unable to work/drive /function		
<b>Paediatrics</b>	Poor visual behaviour in infancy			
<b>Trauma</b>				
<b>Other</b>				

## 7 Level 5: Appointment above 30 days, safe date needs identification per patient

<b>Vitreoretinal</b>	Epiretinal membranes	Macular hole	vitreomacular traction					Other routine appointments
<b>Neuro-ophthalmology</b>	Unexplained loss of vision already investigated by others with normal results	Incidental finding of asymptomatic optic atrophy	Chronic, stable (>1y) diplopia of unknown cause	Monitoring of known intracranial tumours	Incidental finding of asymptomatic anisocoria.	Incidental finding of non-neurological visual field defect by optician		Other routine appointments
<b>Medical Retina and Uveitis</b>	First follow-up post pan-retinal photocoagulation for proliferative diabetic retinopathy /neovascular glaucoma	Moderate to severe NPDR	Branch retinal vein occlusion	Central serous chorioretinopathy	Inflammatory eye disease	Diabetic macular oedema  Postop macular oedema	Haemangiomas	Other routine appointments
<b>Glaucoma</b>	Poorly controlled or unstable glaucoma but not at risk of significant visual loss within 4-6 months	Monitoring of stable glaucoma patient	Suspected glaucoma	Ocular hypertension				Other routine appointments

<b>Adnexal</b>	Inflammatory adnexal disease	Active thyroid eye disease	Blepharospasm <70years old	Blepharospasm >70 years old	Lacrimal patients	Lid malposition	Hemifacial spasm	Other routine appointments
<b>Paediatrics</b>	Amblyopia	Strabismus	Juvenile idiopathic arthritis screening					Other routine appointments
<b>External</b>	Rapidly progressive keratoconus	Routine graft follow ups	Inflammatory external eye disease					Other routine appointments
<b>Trauma</b>								Other routine appointments
<b>Cataract</b>	Cataract or PCO with reduced working/driving/ carer ability marked effect on QoL	Cataract with severe anisometropia affected BV						Routine Cataract
<b>Other</b>			Oncology 6 month follow up					Other routine appointments

## 8 References

---

1. Measuring follow up timeliness and risk for performance reporting, improvement actions and targeting failsafe procedures in England, RCOphth: <https://www.rcophth.ac.uk/wp-content/uploads/2020/03/Measuring-follow-up-timeliness-and-risk-for-performance-reporting-improvement-actions-and-targeting-failsafe-procedures-in-England.pdf>